Immutep Limited (NASDAQ:IMMP - Get Free Report) shares crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.72 and traded as low as $1.61. Immutep shares last traded at $1.68, with a volume of 59,932 shares changing hands.
Immutep Price Performance
The stock's 50-day moving average is $1.70 and its 200-day moving average is $1.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25.
Hedge Funds Weigh In On Immutep
Several large investors have recently made changes to their positions in the business. XY Capital Ltd boosted its position in shares of Immutep by 52.0% during the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock valued at $357,000 after purchasing an additional 56,306 shares in the last quarter. ABC Arbitrage SA acquired a new position in shares of Immutep in the fourth quarter worth about $152,000. Two Sigma Securities LLC acquired a new position in shares of Immutep in the fourth quarter worth about $74,000. OLD Mission Capital LLC acquired a new position in shares of Immutep in the fourth quarter worth about $36,000. Finally, Fortitude Advisory Group L.L.C. acquired a new position in shares of Immutep in the fourth quarter worth about $28,000. Institutional investors own 2.32% of the company's stock.
Immutep Company Profile
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Articles
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
